Clinical Trial Detail

NCT ID NCT02121990
Title Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

fallopian tube carcinoma

peritoneal carcinoma

ovarian carcinoma

Therapies

Bevacizumab + Cisplatin + Olaparib + Paclitaxel

Age Groups: adult

No variant requirements are available.